Rajkumar, S. Vincent

Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer

Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 569

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

Rajkumar, S. V. (2024) · American Journal of Hematology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 534

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 523

Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma

Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 512

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Kumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 446

Clinical Course of Patients With Relapsed Multiple Myeloma

Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings

Multiple Myeloma Research and TreatmentsMultiple Sclerosis Research Studies

Cited by 365

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., et al. (2007) · Leukemia

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 351

Updated Diagnostic Criteria and Staging System for Multiple Myeloma

Rajkumar, S. V. (2016) · American Society of Clinical Oncology Educational Book

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 350

Genomic abnormalities in monoclonal gammopathy of undetermined significance

Fonseca, R., Bailey, R. J., Ahmann, G. J., Rajkumar, S. V., Hoyer, J. D., Lust, J. A., Kyle, R. A., Gertz, M. A., Greipp, P. R., & Dewald, G. W. (2002) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 348

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 317

The multiple myelomas — current concepts in cytogenetic classification and therapy

Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 302

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., Goldschmidt, H., et al. (2020) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 291

Treatment of multiple myeloma

Rajkumar, S. V. (2011) · Nature Reviews Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 289

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

Rajkumar, S. V., Gupta, V, Fonseca, R., Dispenzieri, A., Gonsalves, W. I., Larson, D., Ketterling, R. P., Lust, J. A., Kyle, R. A., & Kumar, S. K. (2013) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 239

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Lacy, M. Q., Allred, J. B., Gertz, M. A., Hayman, S. R., Short, K. D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 222

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

Fonseca, R., Van Wier, S. A., Chng, W. J., Ketterling, R., Lacy, M. Q., Dispenzieri, A., Bergsagel, P. L., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., et al. (2006) · Leukemia

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 213

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsNeutropenia and Cancer Infections

Cited by 212

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 197

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Wang, M., Dimopoulos, M. A., Chen, C., Cibeira, M. T., Attal, M., Spencer, A., Rajkumar, S. V., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2008) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 176

Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study

Landgren, O., Kyle, R. A., Hoppin, J. A., Beane Freeman, L. E., Cerhan, J. R., Katzmann, J. A., Rajkumar, S. V., & Alavanja, M. C. (2009) · Blood

Pesticide Exposure and ToxicityMultiple Myeloma Research and Treatments

Cited by 166

MYC dysregulation in the progression of multiple myeloma

MMRF CoMMpass Network, Misund, K., Keane, N., Stein, C. K., Asmann, Y. W., Day, G., Welsh, S., Van Wier, S. A., Riggs, D. L., Ahmann, G., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 161

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management

Rajkumar, S. V. (2011) · American Journal of Hematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 152

Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management

Rajkumar, S. V. (2012) · American Journal of Hematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 144

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

Gonsalves, W. I., Leung, N., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Dingli, D., Kapoor, P., Go, R. S., et al. (2015) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsRenal cell carcinoma treatment

Cited by 133